Selumetinib

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 736 publications

Mirdametinib in symptomatic neurofibromatosis type 1 plexiform neurofibromas.

Mirdametinib in symptomatic neurofibromatosis type 1 plexiform neurofibromas.

Journal: Expert review of anticancer therapy

Published: March 12, 2026

Patient and caregiver experiences with selumetinib for the treatment of pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas.

Patient and caregiver experiences with selumetinib for the treatment of pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas.

Journal: Neuro-oncology practice

Published: March 09, 2026

Mechanical Stiffening Promotes Growth, Invasion, and Mitogen-Activated Protein Kinase Kinase (MEK) Inhibitor Resistance in 3D Plexiform Neurofibroma Cultures.

Mechanical Stiffening Promotes Growth, Invasion, and Mitogen-Activated Protein Kinase Kinase (MEK) Inhibitor Resistance in 3D Plexiform Neurofibroma Cultures.

Journal: bioRxiv : the preprint server for biology

Published: February 09, 2026

Inhibition of focal adhesion kinase impairs tumor formation and preserves hearing in a murine model of NF2-related schwannomatosis.

Inhibition of focal adhesion kinase impairs tumor formation and preserves hearing in a murine model of NF2-related schwannomatosis.

Journal: Science advances

Published: January 30, 2026

Adverse Events and Toxicity of Systemic Treatments for Uveal Melanoma: A Systematic Review.

Adverse Events and Toxicity of Systemic Treatments for Uveal Melanoma: A Systematic Review.

Journal: Cancers

Published: January 28, 2026

Pharmacokinetics and Safety of Selumetinib Granule Formulation in Children With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas (SPRINKLE; phase I/II).

Pharmacokinetics and Safety of Selumetinib Granule Formulation in Children With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas (SPRINKLE; phase I/II).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: January 27, 2026

Pediatric-Friendly Formulations: Critical to Maximizing Benefit of Novel Therapeutics Such as Selumetinib for Children With Neurofibromatosis and Other Neoplasms.

Pediatric-Friendly Formulations: Critical to Maximizing Benefit of Novel Therapeutics Such as Selumetinib for Children With Neurofibromatosis and Other Neoplasms.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: January 27, 2026

Treatment with Kinase Inhibitors Plus Myo-Inositol as Re-Differentiating Agents in Iodine-Refractory Thyroid Cancers.

Treatment with Kinase Inhibitors Plus Myo-Inositol as Re-Differentiating Agents in Iodine-Refractory Thyroid Cancers.

Journal: Life (Basel, Switzerland)

Published: January 14, 2026

Emerging Molecular Insights and Therapeutic Directions in Neurofibromatosis Type 1 and NF2-Related Schwannomatosis.

Emerging Molecular Insights and Therapeutic Directions in Neurofibromatosis Type 1 and NF2-Related Schwannomatosis.

Journal: International journal of molecular sciences

Published: January 09, 2026

Prolonged Mitogen-Activated Protein Kinase Kinase (MEK) Inhibition Induces Increase in Proteolysis and Compensatory Phosphorylation of MEK and Protein Kinase B (AKT) in Plexiform Neurofibroma Cells.

Prolonged Mitogen-Activated Protein Kinase Kinase (MEK) Inhibition Induces Increase in Proteolysis and Compensatory Phosphorylation of MEK and Protein Kinase B (AKT) in Plexiform Neurofibroma Cells.

Journal: Cells

Published: January 05, 2026

Fatal Pericarditis and Cardiac Tamponade During Selumetinib Treatment for Pericardial Neurofibroma.

Fatal Pericarditis and Cardiac Tamponade During Selumetinib Treatment for Pericardial Neurofibroma.

Journal: The Journal of dermatology

Published: January 05, 2026

Deciphering MAPK dependence in epidermolysis bullosa-associated squamous cell carcinoma: Toward biomarker-guided MEK inhibition.

Deciphering MAPK dependence in epidermolysis bullosa-associated squamous cell carcinoma: Toward biomarker-guided MEK inhibition.

Journal: The Journal of investigative dermatology

Published: December 29, 2025

Showing 1-12 of 736

Last Updated: 04/28/2026